<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6893414\results\search\testTrace\results.xml">
  <result pre="of the macrolide antibiotics, was found to effectively inhibit ZIKV" exact="infection" post="in different cell types and significantly protect A129 mice"/>
  <result pre="and received attention globally. More recently, unexpected outbreaks of ZIKV" exact="infection" post="have occurred in Brazil and rapidly spread from South"/>
  <result pre="safely used by pregnant women, was found to inhibit ZIKV" exact="infection" post="efficiently. Ery-Est, one of the macrolide antibiotics, is the"/>
  <result pre="respiratory syncytial virus and Middle East respiratory syndrome coronavirus (MERS-CoV)" exact="infection" post="respectively, and ivermectin and azithromycin (Azi) were identified to"/>
  <result pre="ivermectin and azithromycin (Azi) were identified to effectively inhibit ZIKV" exact="infection" post="[17,18,19,20,21,22,23]. To the best of our knowledge, this is"/>
  <result pre="detect the cell vitality as previously described [28]. In the" exact="detection" post="using CCK8, orange-colored formazan could be formed by WST-8"/>
  <result pre="The inhibition of Ery-Est against ZIKV in multiple rounds of" exact="infection" post="was performed as previously described [29]. BHK21 cells (2"/>
  <result pre="of ZIKV, the experiment was performed with a multiplicity of" exact="infection" post="(MOI) of 0.1 as previously described [30]. Briefly, BHK21"/>
  <result pre="1% Triton X-100, and 1% DMSO treatments respectively or without" exact="treatment" post="were incubated at 37 Â°C for 2 h. Then,"/>
  <result pre="the top to bottom and detected for E protein by" exact="western blot" post="and viral genomic RNA by RT-qPCR. Anti-E mAb 4G2"/>
  <result pre="be protected if a mouse survived to 21 days post" exact="infection" post="(dpi). The viral RNA loads of sera were measured"/>
  <result pre="susceptible to ZIKV and develop obvious cytopathic effects (CPE) after" exact="infection" post="[38], and the ZIKV-forming plaques were presented visually by"/>
  <result pre="increased. There were scarcely any plaques formed with the Ery-Est" exact="treatment" post="of 10 ÂµM or more, while plaques treated by"/>
  <result pre="assay were generally unchanged. This suggests that Ery-Est inhibits ZIKV" exact="infection" post="in a dose-dependent manner. The 50% inhibitory concentration (IC50)"/>
  <result pre="and Ery treatments. It was found that Ery-Est significantly reduced" exact="infection" post="rates of U-251 MG cells with an IC50 value"/>
  <result pre="7.14 Â± 0.96 ÂµM (Figure 1D). We also developed the" exact="immunofluorescence" post="staining assay to verify the anti-ZIKV activity of Ery-Est"/>
  <result pre="thus, could be detected by CCK8, which could evaluate ZIKV" exact="infection" post="indirectly. As a result, Ery-Est was testified to inhibit"/>
  <result pre="a result, Ery-Est was testified to inhibit ZIKV strain SZ01" exact="infection" post="with IC50 values of 3.55 Â± 0.46 and 3.97"/>
  <result pre="Taken together, these data indicate that Ery-Est notably inhibits ZIKV" exact="infection" post="in different cell types, including neuronal cells. In addition,"/>
  <result pre="Ery-Est against viral growth, Ery-Est was tested to inhibit ZIKV" exact="infection" post="in a multistep growth curve. It was demonstrated that"/>
  <result pre="also shown that Ery-Est could exhibit inhibitory activity against ZIKV" exact="infection" post="even with relatively higher viral doses (Figure S2B), and"/>
  <result pre="viral doses (Figure S2B), and viral titers were reduced by" exact="treatment" post="of different concentrations of Ery-Est. Treatment of 5 ÂµM"/>
  <result pre="group, indicating that Ery-Est remained effective against relatively higher dose" exact="infection" post="of ZIKV. 3.2. Ery-Est Inhibited ZIKV Strains FLR and"/>
  <result pre="cells, we further tested whether Ery-Est could effectively inhibit the" exact="infection" post="of ZIKV (V-ZIKV) produced in one kind of mammalian"/>
  <result pre="cells. Supplementary Figure S3 showed that Ery-Est significantly inhibited V-ZIKV" exact="infection" post="with IC50 value of about 3.66 Â± 0.11 ÂµM,"/>
  <result pre="addition of Ery-Est to BHK21 cells at 0 h post" exact="infection" post="significantly decreased the plaque numbers caused by ZIKV, showing"/>
  <result pre="h, showed gradually lower inhibitory activity but barely suppressed virus" exact="infection" post="from 8 h post infection. Generally, Ery-Est inhibited ZIKV"/>
  <result pre="infection from 8 h post infection. Generally, Ery-Est inhibited ZIKV" exact="infection" post="mainly in the early 2 h stage post infection,"/>
  <result pre="2 h stage post infection, indicating that Ery-Est inhibits ZIKV" exact="infection" post="in the early stage. Next, to confirm the particular"/>
  <result pre="obvious inhibitory effects on viral entry, but barely inhibited ZIKV" exact="infection" post="in the viral post-entry stage. The result was consistent"/>
  <result pre="80% genomic RNA was digested by the RNase after the" exact="treatment" post="of 25 ÂµM Ery-Est, illustrating that Ery-Est may cause"/>
  <result pre="viral integrity. These results indicate that Ery-Est may inhibit ZIKV" exact="infection" post="by destructing the viral integrity, resulting in the release"/>
  <result pre="in placentas and fetal heads from pregnant mice with Ery-Est" exact="treatment" post="was significantly lower than that from mice with Ery"/>
  <result pre="mice with Ery or vehicle treatments (Figure 5B,C). Besides, the" exact="infection" post="rates of placentas and fetal heads were decreased by"/>
  <result pre="penetrated to the placenta and then the fetus, thus reducing" exact="infection" post="rates of placentas and fetuses, as well as blocking"/>
  <result pre="of ZIKV, remains the primary preventive measure. The high throughput" exact="screening" post="of already-approved drugs has been carried out to provide"/>
  <result pre="ZIKV. In our study, Ery-Est was demonstrated to inhibit ZIKV" exact="infection" post="in a dose-dependent manner in plaque assay (Figure 1B,C"/>
  <result pre="still suppress viral growth and exhibit inhibitory activity against ZIKV" exact="infection" post="even with relatively higher viral dose (Figure S2A,B), and"/>
  <result pre="infection even with relatively higher viral dose (Figure S2A,B), and" exact="treatment" post="of 5 ÂµM Ery-Est decreased viral titers by approximately"/>
  <result pre="synthesis of bacteria and is mainly used for Staphylococcus aureus" exact="infection" post="and other diverse bacillosis [45]. To the best of"/>
  <result pre="are constantly discovered [19,20,21,22,23,46], more opportunities for research and clinical" exact="treatment" post="can be provided. The clinical dosage of Ery-Est for"/>
  <result pre="at the dosage of 1 g/day to assess whether antibiotic" exact="treatment" post="could benefit pregnant women with heavy vaginal ureaplasma colonization"/>
  <result pre="women and vaginal use, thus, increases clinical options of the" exact="treatment" post="and prevention for ZIKV infection. Moreover, Ery-Est was demonstrated"/>
  <result pre="indicating it may have a good effect on decreasing fetal" exact="infection" post="risk or reducing fetal symptoms when used for infected"/>
  <result pre="was reported that preexisting DENV antibodies may aggravate the ZIKV" exact="infection" post="through an antibody-dependent enhancement (ADE) effect [54,55], the phenomenon"/>
  <result pre="further repurposed as a novel antiviral drug to treat ZIKV" exact="infection" post="in populations with high risk, particularly pregnant women. Acknowledgments"/>
  <result pre="rounds of infection; Inhibitory activity of Ery-Est against high dose" exact="infection" post="of ZIKV. Figure S3: Inhibition of Ery-Est against ZIKV"/>
  <result pre="Hyg.19524650952010.1016/0035-9203(52)90042-412995440 2.MacnamaraF.N.Zika virus: A report on three cases of human" exact="infection" post="during an epidemic of jaundice in NigeriaTrans. R Soc."/>
  <result pre="Zika virus in the Pacific areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 4.JouannicJ.M.FriszerS.Leparc-GoffartI.GarelC.Eyrolle-GuignotD.Zika virus" exact="infection" post="in French PolynesiaLancet20163871051105210.1016/S0140-6736(16)00625-5 5.Zika Virus Outbreaks in the AmericasAvailable"/>
  <result pre="Optic neuropathy and congenital glaucoma associated with probable Zika virus" exact="infection" post="in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections: Zika virus"/>
  <result pre="infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections: Zika virus" exact="infection" post="could trigger Guillain-Barre syndromeNat. Rev. Neurol.20161218710.1038/nrneurol.2016.3026988905 10.CarteauxG.MaquartM.BedetA.ContouD.BrugieresP.FouratiS.Cleret de LangavantL.de"/>
  <result pre="Acad. Sci. USA2016113144081441310.1073/pnas.161802911327911847 23.WuY.H.TsengC.K.LinC.K.WeiC.K.LeeJ.C.YoungK.C.ICR suckling mouse model of Zika virus" exact="infection" post="for disease modeling and drug validationPLoS Negl. Trop. Dis.20181210.1371/journal.pntd.0006848"/>
  <result pre="proteinPLoS ONE20116e1605910.1371/journal.pone.001605921264311 27.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.QinC.F.JiangS.LuL.et al.A peptide-based viral inactivator inhibits Zika virus" exact="infection" post="in pregnant mice and fetusesNat. Commun.201781567210.1038/ncomms1567228742068 28.XieJ.LiuJ.H.LiuH.LiaoX.Z.ChenY.LinM.G.GuY.Y.LiuT.L.WangD.M.GeH.et al.Tanshinone IIA"/>
  <result pre="in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and chikungunya virus" exact="infection" post="by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based discovery of"/>
  <result pre="effective as and better tolerated than erythromycin estolate for the" exact="treatment" post="of pertussisPediatrics.2004114e96e10110.1542/peds.114.1.e9615231980 47.Raynes-GreenowC.H.RobertsC.L.BellJ.C.PeatB.GilbertG.L.Antibiotics for ureaplasma in the vagina in"/>
  <result pre="box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531 55.LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.LiuR.WangJ.ZhangF.JinX.et al.Dengue immune sera enhance Zika virus" exact="infection" post="in human peripheral blood monocytes through Fc gamma receptorsPLoS"/>
  <result pre="Friend or Foe?Trends Immunol.20163763563610.1016/j.it.2016.08.00627599407 57.MorroneS.R.LokS.M.Structural perspectives of antibody-dependent enhancement of" exact="infection" post="of dengue virusCurr. Opin. Virol.2019361810.1016/j.coviro.2019.02.00230844538 58.SapparapuG.FernandezE.KoseN.BinC.FoxJ.M.BombardiR.G.FremontD.H.DoranzB.J.DiamondM.S.CroweJ.E.et al.Neutralizing human antibodies"/>
  <result pre="crystal violet for plaque visualization and (C) the inhibitions of" exact="infection" post="were calculated. The experiment was tested in triplicate and"/>
  <result pre="Ery. The percentage of infected cells at 48 h post" exact="infection" post="was determined by flow cytometry and normalized to untreated"/>
  <result pre="SZ01 and treated by Ery-Est and Ery, then the ZIKV" exact="infection" post="was evaluated by immunofluorescence staining after 4 days. ZIKV"/>
  <result pre="Ery-Est and Ery, then the ZIKV infection was evaluated by" exact="immunofluorescence" post="staining after 4 days. ZIKV E protein were stained"/>
  <result pre="p &amp;lt; 0.0001. Figure 2 Inhibition of Ery-Est against flavivirus" exact="infection" post="with a broad spectrum and its cytotoxicity. BHK21 cells"/>
  <result pre="MR766, (C) DENV II, and (D) YFV 17D with the" exact="treatment" post="of serial concentrations of Ery-Est and Ery, and then"/>
  <result pre="1% crystal violet for plaque visualization and the inhibitions of" exact="infection" post="were calculated. Huh7 cells (2 Ã— 104) were infected"/>
  <result pre="infected by (E) pseudotyped MERS-CoV and (F) VSV with the" exact="treatment" post="of Ery-Est and Ery, the inhibitory activity was measured"/>
  <result pre="**** p &amp;lt; 0.0001. Figure 3 Early stages of ZIKV" exact="infection" post="were inhibited by Ery-Est. (A) BHK21 cells (2 Ã—"/>
  <result pre="DMSO was added to infected cells for 12 h. Viral" exact="infection" post="of those four experiments were evaluated by plaque assay."/>
  <result pre="&amp;lt; 0.0001. Figure 4 Protective activity of Ery-Est against ZIKV" exact="infection" post="in lethal mouse models. Three groups of A129 mice"/>
  <result pre="1 Ã— 105 plaque forming units (PFU) ZIKV, followed by" exact="treatment" post="of Ery-Est, Ery, and vehicle at 50 mg/kg respectively"/>
  <result pre="placentas, and (C) in fetal heads at 1 day post" exact="infection" post="were measured by RT-qPCR. Three embryos of each pregnant"/>
 </snippets>
</snippetsTree>
